Home » Stocks » Avrobio

Avrobio, Inc. (AVRO)

Stock Price: $17.38 USD -0.06 (-0.34%)
Updated Jul 9, 2020 12:35 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 626.30M
Revenue (ttm) n/a
Net Income (ttm) -81.84M
Shares Out 36.04M
EPS (ttm) -2.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $17.38
Previous Close $17.44
Change ($) -0.06
Change (%) -0.34%
Day's Open 17.44
Day's Range 17.13 - 17.84
Day's Volume 92,004
52-Week Range 9.76 - 29.32

More Stats

Market Cap 626.30M
Enterprise Value 368.60M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 36.04M
Float 29.34M
EPS (basic) -2.74
EPS (diluted) -2.74
FCF / Share -2.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.96M
Short Ratio 4.95
Short % of Float 6.39%
Beta 1.72
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.50
Revenue n/a
Operating Income -84.70M
Net Income -81.84M
Free Cash Flow -74.19M
Net Cash 257.70M
Net Cash / Share 7.15
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -27.35%
ROE -45.05%
ROIC -12,974.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 7
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$37.12*
(113.58% upside)
Low
13.0
Current: 17.38
High
58.0
Target: 37.12
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue----
Operating Income-75.81-46.24-18.39-4.63
Net Income-72.97-46.36-18.65-4.66
Shares Outstanding27.4313.442.242.04
Earnings Per Share-2.66-3.62-8.38-2.44
Operating Cash Flow-67.67-37.65-16.38-3.31
Capital Expenditures-1.59-1.83-0.38-
Free Cash Flow-69.25-39.48-16.77-3.31
Cash & Equivalents1871265.965.36
Net Cash / Debt1871265.965.36
Assets2011337.025.40
Liabilities14.5011.303.660.98
Book Value186122-23.14-4.58
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Avrobio, Inc.
Country United States
Employees 112
CEO Geoff MacKay

Stock Information

Ticker Symbol AVRO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AVRO
IPO Date June 21, 2018

Description

AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.